Last reviewed · How we verify

USRC Kidney Research — Portfolio Competitive Intelligence Brief

USRC Kidney Research pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ferric Citrate 1 gram Oral Tablet Ferric Citrate 1 gram Oral Tablet marketed
Ferric Citrate 1 GM Oral Tablet [AURYXIA] Ferric Citrate 1 GM Oral Tablet [AURYXIA] phase 3 Phosphate binder Dietary phosphate (non-receptor mechanism) Nephrology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Genzyme, a Sanofi Company · 1 shared drug class
  2. SIGA Technologies · 1 shared drug class
  3. Sanofi · 1 shared drug class
  4. Shire · 1 shared drug class
  5. Tanabe Pharma Corporation · 1 shared drug class
  6. University of Colorado, Denver · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for USRC Kidney Research:

Cite this brief

Drug Landscape (2026). USRC Kidney Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/usrc-kidney-research. Accessed 2026-05-16.

Related